Medical Oncologist
Targeted therapy eligibility
Who Is Eligible for — Imatinib?
Imatinib is not prescribed based on cancer type alone. A specific genetic change in your tumour must be confirmed by testing first. Your oncologist arranges this before the drug is considered.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Mutation first — Your oncologist tests for BCR-ABL in CML or KIT and PDGFRA in GIST before imatinib is considered.
- Two confirmed uses — Imatinib is an established first-line treatment for Ph+ CML and for most KIT-mutant GISTs.
- Not all GISTs respond — Certain GIST mutations, particularly PDGFRA D842V, do not respond to imatinib. Your test result decides this.
- A tablet, not an infusion — Imatinib is a daily oral tablet taken at home, not given by drip in a clinic.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Imatinib works only when a specific genetic change is confirmed in your tumour. It is prescribed for chronic myeloid leukaemia with the BCR-ABL fusion gene, and for gastrointestinal stromal tumours with a KIT or PDGFRA mutation. If testing does not find one of these changes, imatinib is not the right treatment for you.
Which cancers is imatinib used for?
Imatinib is a targeted therapy that blocks an abnormal protein driving certain cancers. It is used in two main situations: chronic myeloid leukaemia where the BCR-ABL gene fusion is present, and gastrointestinal stromal tumours where a KIT or PDGFRA mutation is identified.
For CML, the BCR-ABL fusion is present in almost everyone newly diagnosed, so imatinib is the standard starting treatment per ELN and NCCN guidance. A small number of people have a resistance mutation from the outset, which a blood test identifies before treatment begins.
For GIST, imatinib is used for tumours that cannot be removed by surgery, that have spread, or that carry a high risk of returning after surgery. Not all GISTs respond — this depends on which mutation is present, and your pathology report will name the exact change found.
What makes someone eligible for imatinib?
- You have CML and your blood test confirms BCR-ABL positivity — also called Philadelphia chromosome positive (Ph+).
- You have GIST with a confirmed KIT exon 11 mutation, which has the strongest response to imatinib.
- You have GIST with a KIT exon 9 mutation — these tumours can respond, though your oncologist may discuss dose.
- You have GIST with a PDGFRA mutation other than D842V, some of which also respond to imatinib.
- You have localised GIST that was removed surgically and your team is considering imatinib to reduce the chance of it returning.
- Your blood counts and liver function are sufficient to take the drug safely — your oncologist checks these before starting.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
How does eligibility differ between CML and GIST?
| Feature | CML (Chronic Myeloid Leukaemia) | GIST (Gastrointestinal Stromal Tumour) |
|---|---|---|
| Mutation required | BCR-ABL fusion gene — present in nearly all CML | KIT exon 11 or 9, or PDGFRA mutation other than D842V |
| How it is tested | Blood test — PCR or FISH for BCR-ABL | Biopsy tissue — mutation analysis by pathology |
| Who is eligible | Almost all newly diagnosed CML, any phase | Unresectable, metastatic, or high-risk resected GIST with the right mutation |
| When imatinib is not used | Certain resistance mutations at diagnosis — a different TKI is chosen | PDGFRA D842V mutation and wild-type GIST — these do not respond |
| Role in treatment | First-line standard of care per ELN and NCCN | First-line for advanced disease; adjuvant after surgery in selected cases |
What do the terms on your pathology report mean?
- BCR-ABL
- A fusion gene formed when parts of chromosomes 9 and 22 swap places. It produces an abnormal protein that tells CML cells to grow without stopping. Imatinib is designed to block that protein.
- Philadelphia chromosome (Ph+)
- The shortened chromosome 22 that results from the BCR-ABL rearrangement. When your report says Philadelphia chromosome positive, it confirms BCR-ABL is present and that imatinib is likely indicated.
- KIT mutation
- A change in the KIT gene found in most GISTs. It causes tumour cells to grow in an uncontrolled way. Imatinib blocks the KIT protein, which is why KIT-mutant GISTs are the main target for this drug.
- PDGFRA D842V
- A specific mutation in the PDGFRA gene that makes the tumour resistant to imatinib. If your GIST report names this mutation, a different targeted drug is used instead.
- Wild-type GIST
- A GIST with no detectable KIT or PDGFRA mutation. These tumours generally do not respond to imatinib, and your team will consider other treatment approaches.
- Tyrosine kinase inhibitor (TKI)
- The class of targeted drugs to which imatinib belongs. They work by blocking specific enzymes — tyrosine kinases — that cancer cells depend on to grow and survive.
Explore 75 more Blood Cancer Targeted Medicines topics
Drug Deep Dive: Imatinib (Gleevec)
- Adjuvant Imatinib After GIST Surgery: How Many Years?
- BCR-ABL PCR Monitoring: What 'Log Reduction' and 'MR4.5' Mean
- Can You Ever Stop Imatinib? Treatment-Free Remission Explained
- Diet and Nutrition While on Imatinib
- Fertility, Pregnancy and Contraception on Imatinib
- How Does Imatinib Work? The BCR-ABL and KIT Inhibitor Explained
- How Long Does Imatinib Take to Work?
- Imatinib (Gleevec, Veenat, Imatib): The Complete Patient Guide
- Imatinib Interactions: Paracetamol, Antacids and Herbal Medicines
- Imatinib Myths: Lifelong Dependence, Fertility and Generic Quality
- Imatinib Price in India: Brand, Generic and Monthly Cost
- Imatinib Side Effects: The Complete List and Timeline
- Imatinib Success Rate and Survival: An Honest Look at the Numbers
- Imatinib for GIST: How It Differs From CML Treatment
- Imatinib in Elderly Patients and Those With Other Illnesses
- Imatinib vs Nilotinib vs Dasatinib: Choosing a CML Drug
- Muscle Cramps and Bone Pain on Imatinib: What Actually Helps
- Nausea, Stomach Upset and Weight Gain on Imatinib
- Puffy Eyes and Swollen Legs on Imatinib: Managing Fluid Retention
- Taking Imatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Imatinib
- When Imatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Imatinib? Chronic Myeloid Leukaemia and GIST
- Will Insurance or a Government Scheme Pay for Imatinib?
- Work, Travel and Daily Life on Imatinib
Drug Deep Dive: Ibrutinib (Imbruvica)
- Diarrhoea, Joint Pain and Infection Risk on Ibrutinib
- Diet and Nutrition While on Ibrutinib
- Easy Bruising and Bleeding on Ibrutinib: What Is Normal and What Is Not
- Fertility, Pregnancy and Contraception on Ibrutinib
- How Does Ibrutinib Work? The BTK Inhibitor Explained
- How Long Does Ibrutinib Take to Work?
- How Long Will You Stay on Ibrutinib?
- Ibrutinib (Imbruvica, Ibrutix): The Complete Patient Guide
- Ibrutinib Interactions: Blood Thinners, Antifungals and Fish Oil
- Ibrutinib Myths: Lifelong Treatment, Bruising and 'It's Not Real Treatment'
- Ibrutinib Price in India: Brand, Generic and Monthly Cost
- Ibrutinib Side Effects: The Complete List and Timeline
- Ibrutinib Success Rate and Survival: An Honest Look at the Numbers
- Ibrutinib With Rituximab or Venetoclax: Continuous vs Fixed-Duration Therapy
- Ibrutinib in CLL, Mantle Cell Lymphoma and Waldenstrom's
- Ibrutinib in Elderly Patients and Those With Other Illnesses
- Ibrutinib vs Acalabrutinib vs Zanubrutinib: Comparing BTK Inhibitors
- Palpitations, Atrial Fibrillation and High Blood Pressure on Ibrutinib
- Surgery and Dental Procedures on Ibrutinib: The Bleeding Rule
- Taking Ibrutinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Ibrutinib
- When Ibrutinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Ibrutinib? CLL, Mantle Cell Lymphoma and Waldenstrom's Macroglobulinaemia
- Will Insurance or a Government Scheme Pay for Ibrutinib?
- Work, Travel and Daily Life on Ibrutinib
Drug Deep Dive: Rituximab (MabThera)
- Diet and Nutrition While on Rituximab
- Drug, Food and Supplement Interactions With Rituximab
- Fertility, Pregnancy and Contraception on Rituximab
- Hepatitis B Reactivation and Rituximab: The Test You Must Not Skip
- How Does Rituximab Work? The Anti-CD20 Monoclonal Antibody Explained
- How Long Does Rituximab Take to Work?
- How Long Will You Stay on Rituximab?
- Low Antibodies and Repeated Infections After Rituximab
- MabThera vs Biosimilar Rituximab in India: Cost and Equivalence
- R-CHOP and Other Rituximab Combinations Explained
- Rituximab (MabThera, Ristova and biosimilars): The Complete Patient Guide
- Rituximab Infusion Day: Premedication, Duration and What to Expect
- Rituximab Infusion Reactions: Why the First Infusion Is Different
- Rituximab Maintenance: Two More Years of Infusions, and Why
- Rituximab Myths: Vaccines, Immunity and 'Permanent Damage'
- Rituximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Rituximab Side Effects: The Complete List and Timeline
- Rituximab Success Rate and Survival: An Honest Look at the Numbers
- Rituximab in Elderly Patients and Those With Other Illnesses
- Tests and Monitoring While You Are on Rituximab
- When Rituximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Rituximab? B-Cell Lymphoma and CLL
- Why the Same Drug Treats Arthritis and Lymphoma
- Will Insurance or a Government Scheme Pay for Rituximab?
- Work, Travel and Daily Life on Rituximab
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
I have been told I have Ph+ CML. Does that mean I will definitely get imatinib?
Philadelphia chromosome positive CML is exactly what imatinib was designed for, and it is the standard starting treatment for most people with newly diagnosed Ph+ CML according to ELN and NCCN guidance. Whether it is the right first choice for you depends on a few additional factors — your phase of CML, your overall health, and whether any resistance mutations are present at diagnosis. Your haematologist will review these before prescribing.
My GIST biopsy report says KIT exon 11 mutation. What does that mean for imatinib?
KIT exon 11 mutations have the strongest response to imatinib among GISTs, and this result is generally favourable for treatment. It means imatinib is likely to be effective, and it is the mutation your oncologist is looking for when considering this drug. Your team will still review your stage, whether the tumour is operable, and your general health before making a final decision.
What if my mutation means imatinib will not work for me?
If your test finds a mutation that does not respond to imatinib — such as PDGFRA D842V in GIST — there are other targeted drugs your oncologist will consider. Being ineligible for imatinib is not the same as running out of options. Your oncologist will explain the alternative and what it is expected to achieve for your specific situation.
Can imatinib be used for cancers other than CML and GIST?
Imatinib has a small number of other approved uses, including certain rare leukaemias and dermatofibrosarcoma protuberans, a type of skin tumour. These situations are uncommon and require specific testing as well. Outside its approved uses, oncologists do not prescribe imatinib on a trial basis — the biology needs to support it first.
Does imatinib work in blast-phase CML?
Imatinib can be used in blast phase, but response is generally lower than in chronic phase and more intensive treatment is often needed alongside it. Many haematologists prefer a newer and more potent TKI in blast phase, or combine imatinib with chemotherapy. The approach depends on your age, fitness, and whether a stem cell transplant is being considered. Your haematologist will explain the options based on your individual situation.
How long does mutation testing take before I can start imatinib?
For CML, the BCR-ABL blood test usually returns within a few days to two weeks, and many centres start treatment while awaiting confirmation if the diagnosis is otherwise clear. For GIST, mutation analysis on biopsy tissue generally takes one to two weeks. If the original sample is small or inconclusive, a repeat biopsy may add time. Ask your oncologist when the result is expected so you have a clear timeline.